135 related articles for article (PubMed ID: 38712561)
1. A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany.
Siefen AC; Kurte MS; Bauer AM; Cornely OA; Wingen-Heimann S; Kron F
Expert Rev Pharmacoecon Outcomes Res; 2024 May; ():. PubMed ID: 38712561
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Jiang Y; Sarpong EM; Sears P; Obi EN
Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
4. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
Whitney L; Nesnas J; Planche T
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
[TBL] [Abstract][Full Text] [Related]
5. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
7. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
Okumura H; Fukushima A; Taieb V; Shoji S; English M
J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
11. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
12. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
[TBL] [Abstract][Full Text] [Related]
13. Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating
Mori N; Hirai J; Ohashi W; Asai N; Shibata Y; Mikamo H
Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627743
[No Abstract] [Full Text] [Related]
14. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
Rajasingham R; Enns EA; Khoruts A; Vaughn BP
Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
[TBL] [Abstract][Full Text] [Related]
16. The management of
Deac IŞ; Ofrim AM; Fărcaş RA; Grad S; Popa ŞL; Dumitraşcu DL
Med Pharm Rep; 2024 Jan; 97(1):5-11. PubMed ID: 38344334
[No Abstract] [Full Text] [Related]
17. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.
Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M
Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.
McDaniel LF; White MN; Obi EN; Kohinke RM; Lockhart ERS; Chipriano DJ; Chen Y; Everson NA
Infect Dis Ther; 2023 Jan; 12(1):95-107. PubMed ID: 35854204
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
[TBL] [Abstract][Full Text] [Related]
20. The Risk of
Hall RG; Cole TJ; Shaw C; Alvarez CA
Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
